1. Home
  2. BLBD vs DFTX Comparison

BLBD vs DFTX Comparison

Compare BLBD & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blue Bird Corporation

BLBD

Blue Bird Corporation

HOLD

Current Price

$53.38

Market Cap

1.7B

ML Signal

HOLD

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$18.06

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
BLBD
DFTX
Founded
1927
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Construction/Ag Equipment/Trucks
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
BLBD
DFTX
Price
$53.38
$18.06
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
4
Target Price
$67.20
$40.25
AVG Volume (30 Days)
392.7K
1.4M
Earning Date
05-11-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
22.78
N/A
EPS
0.94
N/A
Revenue
$1,480,099,000.00
N/A
Revenue This Year
$6.07
N/A
Revenue Next Year
$6.37
N/A
P/E Ratio
$56.91
N/A
Revenue Growth
9.87
N/A
52 Week Low
$30.15
$14.62
52 Week High
$62.90
$19.62

Technical Indicators

Market Signals
Indicator
BLBD
DFTX
Relative Strength Index (RSI) 40.99 53.21
Support Level $49.55 $16.26
Resistance Level $58.25 $18.21
Average True Range (ATR) 2.03 0.95
MACD -0.95 0.06
Stochastic Oscillator 10.05 43.65

Price Performance

Historical Comparison
BLBD
DFTX

About BLBD Blue Bird Corporation

Blue Bird Corp is an American bus manufacturing company. It is an independent designer and manufacturer of school buses. The company operates in two segments; the Bus segment which involves the design, engineering, manufacture, and sales of school buses and extended warranties; and the Parts segment which includes the sales of replacement bus parts. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada and Rest of the world.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Share on Social Networks: